Additional Information
Book Details
Abstract
Kinase inhibition remains an area of significant interest across academia and in the pharmaceutical industry. There are now many marketed drugs which target kinases and a significant number of compounds are currently in various stages of clinical development. Although there have been a number of publications on kinase inhibition, this is the first to examine the future opportunities and challenges in targeting this important family of enzymes. The book is forward-looking and focuses on a number of key areas for kinase inhibition over the coming years.
Richard A Ward and Frederick W Goldberg have both been working at AstraZeneca in Alderley Park for over 5 years. Richard Ward is a Computational Chemist and Frederick Goldberg is a Medicinal Chemist. They have worked on a significant number of kinase projects and are named on various kinase-related papers and patents and have both presented externally on the subject.